Big pharma is failing to do enough for poor countries
Monday, 14 November 2016
The Financial Times
Gonzalo Viña writes about the 2016 Access to Medicine Index, citing the finding that the pharmaceutical industry is making little progress in key areas, particularly affordability.
Some of the world’s biggest drug companies are failing to do enough to provide medicines to poor countries, and the industry as a whole has made almost no progress in making treatments more affordable, the latest Access to Medicine Index has revealed.
Switzerland’s Roche, Bayer of Germany and Pfizer, Bristol-Myers Squibb and Eli Lilly of the US were among eight companies identified by the Netherlands-based Access to Medicine Foundation that are falling short on a range of measures such as research and development, patent and licensing arrangements and product donations.
The ranking, published every two years by the foundation, is sponsored by the British and Dutch governments alongside the Bill & Melinda Gates Foundation, and looks at how the world’s top 20 drug companies operate in low- and middle-income countries.